Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.59 |
| ▸ | SIGLEC7 | Q9Y286 | 7/20 | 0.51 |
| ▸ | SELL | P14151 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.45 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.45 |
| ▸ | MAG | P20916 | 3/20 | 0.45 |
| ▸ | CD22 | P20273 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21153387 | 0.88 | NANP (0.58) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL15128577 | 0.88 | NANP (0.58) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL29268869 | 0.86 | NANP (0.61) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL7263212 | 0.85 | NANP (0.62) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL7066109 | 0.85 | NANP (0.74) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL13125452 | 0.85 | NANP (0.74) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL28161285 | 0.85 | NANP (0.74) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL2742889 | 0.85 | NANP (0.74) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL8489507 | 0.85 | NANP (0.74) | NANPSIGLEC7SELLSELPMAG | |
| SCHEMBL28106674 | 0.85 | NANP (0.62) | NANPSIGLEC7SELLSELPMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083186-B2 | Methods for assembling scavenging particles | NANOTICS, LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240269319-A1 | METHODS FOR ASSEMBLING SCAVENGING PARTICLES | NANOTICS, LLC | 2024-08-15 | — | — | US | disclosed |
| US-12048710-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-30 | — | — | US | disclosed |
| CN-118027177-A | Diphenyl ring Xin Guijian albumin, albumin-antineoplastic compound nano particle and its preparation method and application | 中山大学孙逸仙纪念医院 | 2024-05-14 | — | — | CN | disclosed |
| US-20240108662-A1 | ENGINEERED CELLS FUNCTIONALIZED WITH IMMUNE CHECKPOINT MOLECULES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2024-04-04 | — | — | US | disclosed |
| WO-2024064957-A2 | GLYCOCAP: A CELL-FREE GLYCOSYLATION PLATFORM FOR CLICKABLE AZIDO-SIALOGLYCAN PRODUCTION | NORTHWESTERN UNIVERSITY (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4251738-A1 | ENGINEERED CELLS FUNCTIONALIZED WITH IMMUNE CHECKPOINT MOLECULES AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116635405-A | Engineering cell functionalized by immune checkpoint molecule and application thereof | 北卡罗来纳大学教堂山分校 | 2023-08-22 | — | — | CN | disclosed |
| US-11684638-B2 | Targeted delivery system, system components, and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-06-27 | — | — | US | disclosed |
| CN-112656956-B | Probe system suitable for in vivo fluorescence and PET imaging tracing of cells and preparation method | 上海交通大学 | 2023-06-27 | — | — | CN | disclosed |
| US-7122703-B2 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1263771-B1 | CHEMOSELECTIVE LIGATION BY USE OF A PHOSPHINE | UNIV CALIFORNIA (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060110782-A1 | cycloalkyne compounds reacting with an azide moiety on a target biomolecule, by biochemical conjugation; for its application in vivo (on the cell surface or intracellularly) or in vitro (synthesis of peptides); labeling | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-05-25 | — | — | US | disclosed |
| WO-2006050262-A2 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050148032-A1 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-07-07 | — | — | US | disclosed |
| US-20030199084-A1 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-10-23 | — | — | US | disclosed |
| US-6570040-B2 | Condensation of specifically engineered phosphine which can provide for formation of amide bond between two reactive partners resulting in product comprising a phosphine moiety or which can be engineered to comprise a cleavable linker | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-27 | — | — | US | disclosed |
| EP-1263771-A2 | CHEMOSELECTIVE LIGATION BY USE OF A PHOSPHINE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016003-A1 | Chemoselective ligation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-07 | — | — | US | disclosed |
| WO-2001068565-A2 | CHEMOSELECTIVE LIGATION BY USE OF A PHOSPHINE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048710-B2 | Compositions and methods for modification of biomolecules | PTMS, QPCT, ANPEP | NANP 478/4885SIGLEC7 148/4885SELL 853/4885 |
| US-20020016003-A1 | Chemoselective ligation | PTMS, QPCT, DNPEP | NANP 396/4885SIGLEC7 583/4885SELL 637/4885 |
| US-20030199084-A1 | Chemoselective ligation | PTMS, QPCT, DNPEP | NANP 396/4885SIGLEC7 583/4885SELL 637/4885 |
| US-20050148032-A1 | Chemoselective ligation | PTMS, QPCT, DNPEP | NANP 396/4885SIGLEC7 583/4885SELL 637/4885 |
| US-20060110782-A1 | cycloalkyne compounds reacting with an azide moiety on a target biomolecule, by biochemical conjugation; for its application in vivo (on the cell surface or intracellularly) or in vitro (synthesis of peptides); labeling | PTMS, QPCT, DNPEP | NANP 215/4885SIGLEC7 200/4885SELL 950/4885 |
| US-20240108662-A1 | ENGINEERED CELLS FUNCTIONALIZED WITH IMMUNE CHECKPOINT MOLECULES AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | NANP 474/4885SIGLEC7 113/4885SELL 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.